


Patent claims


1. Compounds of formula (I):

5



wherein

A is a hydrogen atom; a group of formula $-C(=NR^4)NH_2$,
 10 wherein R^4 is a hydrogen atom, a heteroalkyl, hetero-
 aralkyl, heterocycloalkyl, heteroalkylcycloalkyl,
 hydroxy or alkyloxy group or is, together with one of
 the radicals R^1 , part of a 5- or 6-membered heteroaryl
 or heterocycloalkyl ring; a group of formula
 15 $-NHC(=NR^4)NH_2$; or has one of the following structures:



Ar¹ is an aryl, aralkyl, heteroaryl or heteroaralkyl group,

Ar² is an aryl, aralkyl, heteroaryl or heteroaralkyl group,

the radicals R^1 are, each independently of any other(s), a hydroxy group, a C_1 - C_4 alkyloxy group, an amino group, a C_1 - C_4 alkylamino group, a C_1 - C_4 -dialkylamino group, a cyano group or a halogen atom;

the radicals R^2 , each independently of any other(s), are a hydroxy group, a C_1 - C_4 alkyloxy group, an amino group, a C_1 - C_4 alkylamino group, a C_1 - C_4 -dialkylamino group, a cyano group or a halogen atom;

R^3 is an alkyl, alkenyl, alkynyl, heteroalkyl, aryl, heteroaryl, cycloalkyl, alkylcycloalkyl, heteroalkyl-cycloalkyl, heterocycloalkyl, aralkyl or heteroaralkyl radical;

G is a glycosyl group;

X is a group of formula NR^5 , O, $CONR^5$, NR^5CO , CH_2NR^5 , S, SO, SO_2 , SO_2NH , $NHSO_2$, PO_2NH , $NHPO_2$, CH_2 , CHMe or CO, wherein R^5 is a hydrogen atom, a C_1 - C_4 alkyl, C_1 - C_4 -heteroalkyl, C_7 - C_{12} aralkyl or C_6 - C_{12} heteroaralkyl group;

Y is a group of formula $CONR^6$, $COCONR^6$, NR^6 , O, NR^6CO , S, SO, SO_2 , SO_2NH , $NHSO_2$, PO_2NH , $NHPO_2$, CH_2 , CHMe or CO, wherein R^6 is a hydrogen atom, a C_1 - C_4 alkyl, C_1 - C_4 -heteroalkyl or C_7 - C_{12} aralkyl group;

n is 0, 1, 2, 3 or 4, and

m is 0, 1, 2, 3 or 4,

or a pharmacologically acceptable salt, solvate, hydrate or pharmacologically acceptable formulation thereof; there being excluded compounds in which Y is a group of formula $CONR^6$ and R^3 is a group of formula $-CHR^7-CO-NR^8R^9$, R^7 , R^8 and R^9 being, each independently of the others, a hydrogen atom, an alkyl, alkenyl, alkynyl, heteroalkyl, heteroaralkyl, heteroaryl, aralkyl, cycloalkyl, heterocycloalkyl, alkylcycloalkyl, heteroalkylcycloalkyl or aryl group, or R^8 and R^9 together are part of a heterocycloalkyl or

heteroaryl ring system; there furthermore being excluded compounds wherein Y is a group of formula CO and R³ is a group of formula -NR¹⁰-CHR⁷-CO-NR⁸R⁹, R⁷, R⁸, R⁹ and R¹⁰ being, each independently of the others,
 5 a hydrogen atom, an alkyl, alkenyl, alkynyl, heteroalkyl, heteroaralkyl, heteroaryl, alkylcycloalkyl, heteroalkyl-cycloalkyl, aralkyl, cycloalkyl, heterocycloalkyl or aryl group, or R⁸ and R⁹ and/or R⁷ and R¹⁰ together are part of a heterocycloalkyl or
 10 heteroaryl ring system.

2. Compounds according to claim 1, wherein A is a group of formula -C(=NH)NH₂.
- 15 3. Compounds according to claim 1 or 2, wherein Ar¹ is a phenyl or heteroaryl group having 5, 6, 7, 8, 9 or 10 carbon ring atoms and 1, 2, 3 or 4 ring hetero atoms selected from O, S and N.
- 20 4. Compounds according to claim 1 or 2, wherein Ar¹ is a phenyl group to which the groups A and X are bonded in positions meta to one another.
- 25 5. Compounds according to one of claims 1, 2, 3 or 4, wherein Ar² is a phenyl group.
6. Compounds according to one of claims 1, 2, 3, 4 or 5, wherein X is an NH group.
- 30 7. Compounds according to one of claims 1, 3, 4, 5 or 6, wherein n is 0 or 1.
8. Compounds according to one of claims 1, 2, 3, 4, 5, 6 or 7, wherein R¹ is a hydroxy group.

9. Compounds according to one of claims 1, 2, 3, 4, 5, 6, 7 or 8, wherein m is 0 or 1.
10. Compounds according to one of claims 1, 2, 3, 4, 5, 6,
5 7, 8 or 9, wherein Y is a group of formula CONH.
11. Compounds according to one of claims 1, 2, 3, 4, 5, 6,
7, 8, 9 or 10, wherein R³ is a group of formula
-U-V-W, wherein U is an optionally substituted
10 C₆-C₁₀aryl group or an optionally substituted hetero-
aryl group containing from 5 to 10 ring atoms and 1,
2, 3 or 4 hetero atoms selected from O, S and N; V is
a direct bond, an oxygen atom, a sulphur atom, a group
of formula NR¹¹ (R¹¹ being a hydrogen atom, a
15 C₁-C₄alkyl, C₁-C₄heteroalkyl, C₇-C₁₂aralkyl or
C₆-C₁₂heteroaralkyl group), CO, SO, SO₂ or SO₂NH, and W
is a hydrogen atom, an alkyl, alkenyl, alkynyl,
heteroalkyl, aryl, heteroaryl, cycloalkyl, alkylcyclo-
alkyl, aralkyl, heteroalkylcycloalkyl, heterocyclo-
20 alkyl or heteroaralkyl radical.
12. Compounds according to claim 11, wherein U is an
optionally substituted phenyl group.
- 25 13. Compounds according to claim 11 or 12, wherein V is a
direct bond or a carbonyl group.
14. Compounds according to claim 11, 12 or 13, wherein W
is a C₁-C₄alkyl group, a C₁-C₄heteroalkyl group, an
30 optionally substituted phenyl group, an optionally
substituted C₃-C₇cycloalkyl group, an optionally
substituted heterocycloalkyl group having 3-7 ring
atoms and 1, 2 or 3 hetero atoms (selected from O, S
and N) or an optionally substituted heteroaryl group
35 having 5 or 6 ring atoms and 1, 2, 3 or 4 hetero atoms
selected from O, S and N.

15. Pharmaceutical compositions comprising a compound according to claims 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 or 14 and, optionally, carrier substances and/or adjuvants.
16. Use of a compound or of a pharmaceutical composition according to one of claims 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15 in inhibiting factor Xa.
17. Use of a compound or of a pharmaceutical composition according to one of claims 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15 in the treatment and/or prevention of thromboembolic conditions, arterial restenosis, septicaemia, cancer, acute inflammation or other conditions mediated by factor Xa activity.
18. Use of a compound or of a pharmaceutical composition according to one of claims 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15 for utilisation in vascular surgery.